Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?
Mené sur 111 patients atteints d'une tumeur solide de stade avancé, cet essai de phase IB évalue la dose maximale tolérée du pegilodecakin (interleukine-10 pégylée) en combinaison avec un anti-PD1 (pembrolizumab ou nivolumab) et analyse ses caractéristiques pharmacocinétiques
With the activity of checkpoint inhibitor monotherapy well documented in several diseases, attention has turned to developing effective combinations. Adding to the backbone of PD-1 inhibition, perhaps the most successful combination strategy to date has been with CTLA-4 inhibition. The combination of nivolumab (a PD-1 inhibitor) with ipilimumab (a CTLA-4 inhibitor) has been approved by the US Food and Drug Administration for the treatment of melanoma, renal cell carcinoma, and mismatch repair deficient or microsatellite unstable colorectal cancer. However, not all pairings of immunotherapy have been successful. A phase 3 study that assessed the combination of the IDO1 inhibitor epacadostat with pembrolizumab (a PD-1 inhibitor) in patients with advanced melanoma showed no benefit versus pembrolizumab with placebo. The findings from this study suggested that not all immunotherapy combinations will have clinical synergy in an unselected population.
The Lancet Oncology , commentaire, 2018